Background: A devastating aspect of Alzheimer's disease (AD) is the progressive deterioration of memory due to neuronal loss. Amyloid precursor protein (APP) occupies a central position in AD and APP-derived amyloid-b (Ab) peptides are thought to play a pivotal role in disease pathogenesis. Nonetheless, it is becoming clear that AD etiology is highly complex and that factors other than Ab also contribute to AD pathogenesis. APP intracellular domain (AICD) is generated together with Ab and we recently showed that AICD transgenic mice recapitulate pathological features of AD such as tau hyperphosphorylation, memory deficits and neurodegeneration without increasing the Ab levels. Since impaired adult neurogenesis is shown to augment memory deficits in AD mouse models, here we examined the status of adult neurogenesis in AICD transgenic mice.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a gradual decline in memory and executive functions. Mounting evidence suggests Amyloid precursor protein (APP) and presenilins are central molecules in the pathophysiology of AD [1, 2] . Aided by presenilins, APP undergoes constitutive proteolysis to produce multiple fragments including amyloid b (Ab) peptides, which form senile plaques. A vast number of studies have shown that Ab plays a pivotal role in the pathophysiology of AD [2] and it is thought that Ab peptides, in an as yet uncertain form, trigger a cascade of downstream deleterious events that eventually results in AD. Ab peptides are shown to hyperphosphorylate tau [3] , induce neuronal cell death in vitro, and cause memory deficits in mice [4] . They are also implicated in causing silent seizures [5] and in the impairment of adult neurogenesis in AD mouse models [6] [7] [8] [9] [10] .
The process of neurogenesis occurs mostly during embryogenesis but also persists during adulthood in the subventricular zone and subgranular zone (SGZ) of the hippocampus. There is increasing evidence that adult hippocampal neurogenesis plays an important role in learning and memory [11] . Increased adult neurogenesis enhances hippocampal-dependent learning and memory [12] whereas decreased neurogenesis impairs it [13] . Also, drugs that increase hippocampal neurogenesis also increase learning and memory [14] and hippocampal neurogenesis is known to decline with aging [15] . Adult neurogenesis is important for maintaining spatial memory function [13, 16] , which is characteristically lost in AD patients. Thus, impaired neurogenesis is being recognized as a significant pathological feature of AD since it can further exacerbate the memory decline caused by neuronal loss.
Although, Ab peptides have been known to play a pivotal role in AD pathology, it is becoming increasingly clear that not all aspects of AD can be accounted for by Ab alone [17, 18] . Findings from such diverse lines of investigation as neuroimaging, clinical trials and preclinical observations suggest that non-Ab factors also contribute to memory deficits in AD. The cleavage of APP by presenilins, which generates Ab, also releases APP Intracellular domain (AICD) from the membrane. AICD modulates gene transcription in vitro [19, 20] , alters signaling pathways and exerts deleterious effects in tissue culture cells [21, 22] , which could cause AD-like features in vivo. Indeed, AICD expressing transgenic mice recapitulate such AD pathologies as activation of glycogen synthase kinase-3b (GSK3b), phosphorylation and aggregation of Tau, deficits in working memory and abnormal neural activity and silent seizures [23] [24] [25] . Interestingly, these pathologies were observed without appreciable changes in APP metabolism or Ab generation [24] . Since AICD levels are elevated in human AD brains [24] , these findings raise the possibility that AICD, in addition to Ab, significantly contributes to AD pathogenesis.
In this study, we report that AICD transgenic mice also exhibit impaired adult neurogenesis by reducing neuronal proliferation and survival. This impairment is observed even in the absence of endogenous APP demonstrating that AICD alone is capable of inducing the deleterious effects. Importantly, the defective adult neurogenesis is prevented by blocking neuroinflammatory changes indicating that neuroinflammation plays a much broader role in AD pathogenesis than previously thought.
Results

Adult hippocampal progenitor cell (HPC) proliferation is reduced in AICD transgenic mice
We measured HPC proliferation in the SGZ by injecting male AICD transgenic mice (line FeCc25) at 1.5, 3 or 12 months of age daily with BrdU for 3 days. Mice were sacrificed 24 hours after the last injection, brains were harvested, fixed and free-floating sections were prepared. We used male mice in this study to avoid the confounding effects of estrus cycle and gonadotrophins on adult neurogenesis in female animals [26] . Brain slices were immunostained with anti-BrdU antibody and BrdU-positive (BrdU+) cells were quantified in the SGZ (defined as the region spanning the border of granule cell layer and hilus with two cell layers into the granule cell layer and hilus) of the entire rostrocaudal extent of the hippocampus. At 1.5 months, the numbers of BrdU+ cells in FeCc25 mice were similar to that observed in nontransgenic control littermates (Fig. 1A,B) . However, 3-month-old FeCc25 mice exhibited reduced BrdU+ cells compared to wildtype animals (Fig. 1C) . Since FeCc25 transgenic mice co-express AICD and Fe65 (which binds and stabilizes AICD), we performed an analogous experiment on Fe27 transgenic mice, which express Fe65 alone [23] . Fe27 mice showed a similar number of BrdU+ cells as the non-transgenic controls (Fig. 1C, E) , indicating that AICD is required to observe impaired HPC proliferation in 3-month-old mice. The deficits in HPC proliferation were also observed in 12-month-old AICD transgenic mice (p,0.05; Fig. 1D , E). Animals older than 12 months were not studied because at this stage even the wild-type mice showed a very low level of adult neurogenesis. Together, these data suggest that AICD impairs adult HPC proliferation in vivo.
Decreased hippocampal neurogenesis in AICD transgenic mice
A majority of newborn cells in the SGZ of adult animals do not survive, and the surviving cells differentiate into neurons or glia [27] . To examine whether reduced HPC proliferation is also accompanied by reduced neurogenesis, we immunostained the brain sections with anti-doublecortin (DCX) antibody. DCX is a microtubule binding protein that is expressed by immature neurons but not by glia. At 3 months of age, wild-type mice showed a large number of highly branched DCX+ cells in the SGZ, with branch tips extending into the molecular layer ( Fig. 2A) . By contrast, the staining was severally diminished in age-matched FeCc25 mice and there was a decrease in the number of DCX+ cells ( Fig. 2A, 2D ) as well as in the extent of arborization (see Fig. 2C ). As observed above, the reduction in the number of DCX+ persisted in 12-month-old mice (Fig. 2B, 2D) . Collectively, these results demonstrate that reduced HPC proliferation is accompanied by decreased neurogenesis in AICD transgenic mice and that these deficits are apparent at 3 months of age and continue to at least 12 months of age.
AICD impairs cell survival but not cell differentiation in hippocampus
We further corroborated the finding that AICD transgenic mice show impaired HPC proliferation by determining the cell survival and differentiation of the newborn cells. To measure cell survival, we injected mice with BrdU for three consecutive days and sacrificed them either one day or four weeks after the last injection (Fig. 3A) . Most newborn granular cells die during this time period and the surviving cells differentiate into neurons or glia. Quantification of BrdU+ cells showed that survival of the newborn cells (the ratio of BrdU+ cells after 4 weeks to the BrdU+ cells after 1 day) was decreased (p,0.01) in FeCc25 mice (Fig. 3B) . Roughly 19% and 14% of newborn cells in wild-type animals and in FeCc25 mice survived after 4 weeks respectively.
We also determined the differentiation of newborn cells into neurons and glia by performing double-immunostaining using neuronal and astrocytic markers (Fig. S1 ). Brain sections were incubated with anti-BrdU antibody and anti-NeuN antibody (to mark mature neurons) or anti-GFAP antibody to identify astrocytes. There were no significant differences in the percentage of 'NeuN+BrdU' double-labeled cells and approximately half of the newborn cells matured into neurons in both FeCc25 and wildtype mice (Fig. 3C) . Similarly, there were no significant differences in the proportion of BrdU+ cells that matured into astrocytes (Fig. 3D) . Together, these results indicate that AICD decreases HPC proliferation and survival without affecting cell differentiation.
AICD impairs HPC proliferation in mice lacking APP
Adult neurogenesis is reduced in many mouse models of AD and this reduction may be caused by multiple factors [reviewed in 6] . We previously showed that APP processing and Ab levels were unchanged in 3-month-old FeCc25 mice compared to control mice [24] . Thus, Ab probably plays no role in reduced adult neurogenesis in FeCc25 animals. However, to address this issue unambiguously, we crossed FeCc25 mice with APP knockout animals and obtained AICD-expressing APP 2/2 mice. 3-monthold FeCc25;APP 2/2 mice were injected with BrdU for 3 days, brains were harvested on the 4 th day and sections were immunostained for BrdU (Fig. 4A , B) or DCX (Fig. 4C ). The lack of APP did not seem to affect adult neurogenesis since the number of BrdU+ cells in APP 2/2 animals ( Fig. 4B ) was similar to that seen in wild-type animals (see Fig. 1B ). However, there was a small but significant decline (p,0.05) in the number of BrdU+ cells in the SGZ of FeCc25;APP 2/2 ( Fig. 4 A, B) . These results unambiguously show that AICD, in the absence of endogenous Ab, can impair HPC proliferation in vivo. We examined the DCX+ immature neurons in the SGZ of these mice and found that FeCc25;APP 2/2 animals displayed a reduced number of DCX+ cells compared to APP 2/2 mice at 3 months of age (Fig. 4C, 4D ).
Also, the DCX+ cells showed reduced arborization in FeCc25;APP 2/2 animals ( Fig. 4C , right panels). We next determined the level of HPC proliferation in two established mouse models of AD. APPPS1 mouse model expresses 'Swedish' mutant APP and M146L mutant presenilin [28] whereas R1.40 mice express only 'Swedish' mutant APP [29] . We observed a reduction in HPC proliferation in 3-month-old APPPS1 mice but not in R1.40 animals (Fig. S2 ) even though both mouse models show elevated levels of Ab. We do not know whether R1.40 mice show neurogenesis defects at older ages but at a minimum, these results show that an elevation in Ab alone does not necessarily result in reduced neurogenesis. In any case, our findings confirm the previous results of reduced adult neurogenesis in mouse AD models and extend them to show that AICD, without Ab, is also able to impair HPC proliferation.
Treatment with NSAIDs prevents the deficits in HPC proliferation and neurogenesis
We next explored the potential mechanisms underlying the inhibitory effects of AICD. Impairment of adult neurogenesis by AICD in FeCc25 mice is probably not mediated by cellautonomous mechanisms because AICD expression is driven by the CaMKIIa promoter, which is active only in mature neurons [30] . However, since a number of factors including environmental stress and neuroinflammation are known to inhibit adult neurogenesis [31, 32] we determined whether FeCc25 mice showed signs of neuroinflammation. Unexpectedly, we observed a dramatic increase in the recruitment of CD45+ microglia in 12 week-old FeCc25 mice compared to wild-type mice (Fig. 5A) . We also observed an increased expression of several proinflammatory cytokines raising the possibility that a proinflammatory environment in FeCc25 mice was responsible for the reduction in adult neurogenesis. To test this hypothesis, we treated mice with ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), by feeding animals a drug-containing diet (375 ppm) for 9 weeks beginning at 3 weeks of age. Figure 5A shows that this regimen of ibuprofen treatment completely blocked the recruitment and activation of microglia in 3-month-old mice. Concomitantly, the number of BrdU+ cells in ibuprofen-fed FeCc25 mice increased significantly and were comparable to those seen in wild-type mice (Fig. 5B, C) . Compared to FeCc25 mice on the control diet, ibuprofen-fed FeCc25 mice showed a 28% increase in the number of BrdU+ cells in SGZ (p,0.05). The NSAID diet did not increase the number of BrdU+ cells in wild-type mice (p = 0.31). We also performed DCX immunostaining on ibuprofen-treated animals and noticed an increase in DCX+ cells in ibuprofen-treated FeCc25 mice (Fig. 5D) . After the ibuprofen treatment, the DCX+ cells in AICD transgenic mice were morphologically indistinguishable from those in wild-type mice (Fig. 5E ).
Since ibuprofen is also known to possess off-target effects (non-COX2), we used another NSAID, naproxen, to see whether it was able to block neurogenesis defects in AICD mice. Like above, AICD mice were fed naproxen-containing diet for 9 weeks and the brains were analyzed (Figure 6 A-D) . Indeed, treatment with naproxen also resulted in increased BrdU incorporation in the dentate gyrus ( Figure 6A ) and quantification showed that the deficits were completely rescued (Fig. 6B) . Similarly, naproxentreated mice showed increased DCX-staining that was comparable to that seen in wild-type mice ( Figure 6C, D) . Thus, these data establish that NSAID treatment rescues the deficits in adult neurogenesis in AICD mice by blocking neuroinflammation.
Discussion
Here we show that AICD impairs adult hippocampal neurogenesis in an age-dependent manner. Adult neurogenesis was normal in 6-week-old AICD transgenic mice but was reduced at 3 months of age and the impairment continued until at least 12 months of age. This impairment was due to decreased cell proliferation and survival and not due to altered differentiation. The defective neurogenesis is mediated by non-cell-autonomous mechanisms involving proinflammatory changes. The important finding of this study is that impaired adult neurogenesis in AD is due to neuroinflammation and the novelty is that we provide compelling evidence that overexpression of AICD impairs adult neurogenesis without Ab.
An increasing number of studies indicate that adult neurogenesis plays an essential role in normal memory function [11, 33] . Inhibition of adult neurogenesis impairs certain kinds of memory, such as spatial learning [13, 16] . Since the loss of spatial memory is a prominent neurological feature of AD, we suggest that impaired adult neurogenesis is especially detrimental in AD. Indeed, a vast number studies have demonstrated deficits in adult neurogenesis in amyloid-based mouse models of AD [6] [7] [8] [9] [10] 31, 34] , although a conflicting study has also been reported [35] . In AICD mice, impaired neurogenesis is first observed at 3 months, which precedes memory deficits by about 4-5 months [24] . Interestingly, impaired adult neurogenesis is also detected much before the appearance of other AD-features in APPswe/PS1dE9 [9] and 3xTgAD [14] mouse models of AD. Thus, deficient adult neurogenesis is a significant pathological factor in AD and our findings suggest that therapies against AD will be more effective when supplemented with treatments that stimulate adult neuro- genesis (such as exercise) or prevent impaired adult neurogenesis (such as anti-inflammatory drugs). Indeed, our preliminary studies show that NSAID treatment improves working memory deficits in the Y-maze paradigm in older (.14 month) AICD transgenic mice.
The finding that treatment with ibuprofen or naproxen prevented neurogenesis defects is of relevance to AD and supports the potential of NSAIDs as prophylactic therapeutic agents [36] . How AICD overexpression results in sustained neuroinflammation is currently under investigation but our preliminary findings suggest that AICD activates stress-kinase pathways and upregulates expression of proinflammatory cytokines. Increased levels of proinflammatory cytokine are reported in serum and CSF from AD patients [37, 38] and neuroinflammation is recognized as a significant pathological event in AD [39, 40] . A mutation in presenilin that alters APP processing inhibits adult neurogenesis in vivo by activating the microglia and elevating the cytokine levels [31] . Proinflammatory conditions are known to downregulate neurogenesis and blocking inflammation has been shown to restore impaired neurogenesis [32] . At present the reasons why proinflammatory environment impairs proliferation and survival more potently but leaves neuronal maturation more or less intact are not clear. Multiple studies have shown the inhibitory effects of individual inflammatory factors (such as TNF-a, IFN-c, IL-6) on proliferation but variable effects on maturation [reviewed in 41]. NPC proliferation is orchestrated by temporal and spatial cues and involves expression of various transcription factors. It seems likely that NPC proliferation is more sensitive to the gene expression changes brought about by proinflammatory cytokines. In any case, chronic neuroinflammation in AD is likely to impair adult neurogenesis and aggravate the loss of hippocampal neurons. Interestingly, retrospective epidemiological studies [36] have shown that long-term use of NSAIDs exert a protective effect against developing AD (although short-term prospective use of NSAID was not protective) and this effect is proposed to be mediated by modulation of Ab levels [42] . Since both drugs, ibuprofen and naproxen, protected against AICD-induced defects in adult neurogenesis, we propose that NSAIDs exert beneficial effects independent of Ab modulation. Although our data show that inflammation plays a pivotal role in impaired neurogenesis, it is possible that AICD impairs neurogenesis also by stimulating GSK-3b activity [23] . Activation of GSK-3b alters the wnt signaling pathway and perturbs neurogenesis in mice [43, 44] and in AD patients [45] .
The observation that AICD transgenic mice lacking Ab exhibit impaired neurogenesis further strengthens the evidence that AICD also contributes to AD pathology. Although a vast amount of data support the pivotal role of Ab peptides in AD pathogenesis [1, 2] , it has become clear that AD etiology is complex and that a single causative agent cannot account for all of the available data [17, 18] . AICD causes apoptosis in vitro [21] and induces tau hyperphosphorylation and aggregation, aberrant neuronal activity, memory deficit and neurodegeneration in vivo [24, 25] . Because AICD levels are also elevated in human AD brains [24] , we had hypothesized that AICD makes significant contributions to AD pathogenesis, and the present study further supports this hypothesis. Interestingly, a recent study showed that AICD signaling occurs predominantly through the amyloidogenic processing of APP [46] . This raises the possibility that the harmful effects of amyloidogenic processing are mediated by both increased Ab as well as elevated AICD (Fig. 6E) and may explain the disappointing results from Ab-focused clinical trials. Future studies are needed to assess the individual contribution of each peptide to AD pathogenesis.
In conclusion, our study shows that AICD transgenic mice exhibit impaired adult hippocampal neurogenesis in an Abindependent manner. More importantly, NSAID treatment had a protective effect against the neurogenesis defects. Together, these findings provide evidence for non-amyloid mechanisms that potentially exacerbate neuronal loss in AD and suggest that inflammation plays a much broader role in AD pathogenesis than previously appreciated.
Methods
Ethics Statement
All experiments were approved by the Institutional Animal Care and Use Committee of The Cleveland Clinic (Protocol Number: 08355).
Transgenic mice
Transgenic mice co-expressing the AICD-59 and Fe65 (FeCc25 line) or Fe65 alone (Fe27) in C57BL/6 background have been described previously [23, 24, 47] . Both transgenes are active in the brain under the control of the CAMKIIa promoter. For all experiments non-transgenic littermates or C57BL/6 mice were used as wild-type controls. APP 2/2 have been described in detail previously [48] APPPS1 and R1.40 animals have been previously described in detail [28] , [29] . To generate FeCc25/APP 2/2 mice that would express AICD59 and Fe65 on APP null background, FeCc25 hemizygous mice were bred with APP +/2 mice to obtain FeCc25/APP +/2 mice in the F1 generation. Subsequently, FeCc25/APP +/2 mice were bred with APP +/2 to produce F2 FeCc25/APP 2/2 , FeCc25/APP 2/+ , APP 2/2 and APP +/2 mice. All animals were housed under standard conditions with 4-5 mice per cage. Table 1 shows the various genotypes of mice used with their treatments groups.
5-Bromo-2-deoxyuridine injection and tissue preparation
To avoid the effects of gender and gonadotropic hormones on adult neurogenesis, only male mice were used throughout the study. To determine cell proliferation, mice were injected once daily with 5-Bromo-2-deoxyuridine (BrdU; 100 mg/kg, i.p.) for three consecutive days. On the day following the last BrdU injection, animals were anesthetized and transcardially perfused with ice-cold phosphate-buffered saline (PBS) followed by PBS containing 4% paraformaldehyde. Brain were removed and fixed in PBS containing 4% paraformaldehyde overnight at 4uC, cryoprotected in 30% sucrose in PBS, embedded using OCT compound (Sakura Finetek, Torrance, CA, USA) and stored at 280uC. To determine long-term cell survival and maturation, identified in box C and enlarged in D for wild-type (left) and FeCc25 mice (right). Error bars represent S.E.M. Scale bar = 100 mm. n = 4 for WT, FeCc25 and WT with naproxen and n = 6 for FeCc25 with naproxen. E. A schematics of how amyloidogenic processing of APP could bring about deleterious effects via both AICD and Ab peptides. Amyloidogenic processing [1] of APP generates Ab and promotes AICD signaling [45] . Ab peptides impair adult neurogenesis possibly by causing [2] an imbalance in GABAergic and Glutamatergic transmissions [10] whereas AICD does so by inducing [3] neuroinflammation (this study). Multiple studies have also shown that both Ab and AICD peptide fragments cause [4] other AD-pathological (including tau hyperphosphorylation, neuronal cell loss, silent seizures, memory deficits) features in mice (dashed arrows). doi:10.1371/journal.pone.0011866.g006 animals were killed 28 days after the final injection of BrdU. The brains were processed as described above.
Immunohistochemistry
Hemi-brains were fixed overnight in 4% paraformaldehyde in PBS, sunk in 30% sucrose and embedded in OCT. 30 mm sagittal sections were cut and every 12 th section was used. Antibodies used were BrdU (Abcam, 1:500) and doublecortin (SantaCruz, 1:1000). Remaining details are given in Supplemental Methods S1.
Stereological counts
The total number of BrdU+ or DCX+ cells in the subgranular zone of the dentate gyrus was quantified using unbiased stereological methods. BrdU+ or DCX+ cells were counted from every sixth section using a 40X objective throughout the entire rostro-caudal extent of the dentate gyrus (bregma 21.0 mm to 22.80 mm). Cells were counted from both halves of the brain within the granular cell layer (GCL) and adjacent SGZ up to a two-cell body-wide zone along the border between the GCL and the hilus. The experimenter counting the cells was blinded to the genotype and experimental modification of the mice. The total number of cells was obtained by multiplying the number of BrdU+ or DCX+ cells with inter section interval and adding them together for the entire hippocampus.
Non-steroidal anti-inflammatory drug (NSAID) diet
Ibuprofen or naproxen (both from Sigma Aldrich) was formulated into standard animal chow by Research Diets at a final concentration of 375 ppm. Male FeCc25 and non-transgenic littermates were fed drug-supplemented or control chow for 9 weeks. Mice were killed at the end of the experimental period and processed for histology or biochemical analyses. For neurogenesis assays, animals were injected with BrdU for three consecutive days before sacrificing as described above.
Statistics
Statistical analysis was performed using GraphPad prism 3.1. The results are expressed as mean 6 standard errors of mean (SEM).
Rest of the protocols is described in Supplemental Methods (Methods S1).
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